BRCA2 and cancer: These findings underscore the need to optimise early detection strategies in men with a high genetic risk—particularly germline mutations in BRCA2—with early screening performed before age 45 or, in patients with a family member diagnosed with cancer, 10 years before the age of diagnosis.